Combining enhanced imaging capabilities, workflow efficiencies and artificial intelligence (AI)-enabled technology to improve the diagnosis and management of health conditions in women, Samsung has launched the V6 ultrasound system.
Advances in artificial intelligence (AI) technology and image sharing tools with Samsung’s new V6 ultrasound platform may facilitate enhanced workflow efficiencies in the management of women’s health conditions.
Samsung noted that key advances with the V6 ultrasound system include:
• one-click fetal growth measurements with the semi-automated BiometryAssist™ feature;
• AI-enabled uterus measurements to help detect uterine-related abnormalities with UterineAssist™; and
• real-time image sharing between sonographers and referring physicians with the SonoSync™ feature.
The V6 ultrasound platform also features a miniER7 endocavity transducer, which gives clinicians a 180-degree field of view, a frequency range between 2 and 12 MHz, and design enhancements that may enhance patient comfort, according to Samsung.
“The V6 was developed with the clinical needs of women’s health and urology specifically in mind,” said Tracy Bury, a women’s health segment leader for Boston Imaging, the United States headquarters of Samsung’s digital radiography and ultrasound business. “We’re proud to offer a new product that is not only accessible to a broad group of clinicians but also has innovative, automated features that can make patient care simpler and more efficient.”
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.